DK0738147T3 - Anvendelse af riluzol ved behandling af mitochondriesygdomme - Google Patents

Anvendelse af riluzol ved behandling af mitochondriesygdomme

Info

Publication number
DK0738147T3
DK0738147T3 DK95906378T DK95906378T DK0738147T3 DK 0738147 T3 DK0738147 T3 DK 0738147T3 DK 95906378 T DK95906378 T DK 95906378T DK 95906378 T DK95906378 T DK 95906378T DK 0738147 T3 DK0738147 T3 DK 0738147T3
Authority
DK
Denmark
Prior art keywords
treatment
pct
riluzole
mitochondrial diseases
date jul
Prior art date
Application number
DK95906378T
Other languages
English (en)
Inventor
Jean-Marie Stutzmann
Jean-Christophe Delumeau
Michel Martinet
Michel Reibaud
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of DK0738147T3 publication Critical patent/DK0738147T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK95906378T 1994-01-12 1995-01-09 Anvendelse af riluzol ved behandling af mitochondriesygdomme DK0738147T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400249A FR2714828B1 (fr) 1994-01-12 1994-01-12 Application du riluzole dans le traitement des maladies mitochondriales.
PCT/FR1995/000023 WO1995019170A1 (fr) 1994-01-12 1995-01-09 Application du riluzole dans le traitement des maladies mitochondriales

Publications (1)

Publication Number Publication Date
DK0738147T3 true DK0738147T3 (da) 2000-07-10

Family

ID=9458947

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95906378T DK0738147T3 (da) 1994-01-12 1995-01-09 Anvendelse af riluzol ved behandling af mitochondriesygdomme

Country Status (14)

Country Link
US (1) US5686475A (da)
EP (1) EP0738147B1 (da)
JP (1) JP3585045B2 (da)
AT (1) ATE191342T1 (da)
AU (1) AU1458495A (da)
DE (1) DE69516110T2 (da)
DK (1) DK0738147T3 (da)
ES (1) ES2145902T3 (da)
FR (1) FR2714828B1 (da)
GR (1) GR3033005T3 (da)
IL (1) IL112288A (da)
PT (1) PT738147E (da)
WO (1) WO1995019170A1 (da)
ZA (1) ZA95150B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267375A1 (en) 1996-10-01 1998-04-09 Mitsunobu Yoshii Mitochondrial membrane stabilizer
US5922746A (en) * 1997-03-27 1999-07-13 Allergan Inhibition of noninactivating Na channels of mammalian optic nerve as a means of preventing optic nerve degeneration associated with glaucoma
FR2774592B1 (fr) * 1998-02-06 2000-03-17 Rhone Poulenc Rorer Sa Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
FR2774908B1 (fr) * 1998-02-17 2000-06-23 Centre Nat Rech Scient Utilisation d'inhibiteur de la liberation du glutamate dans le traitement de l'ischemie retinienne
FR2787028B1 (fr) * 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
AU4424500A (en) * 1999-04-29 2000-11-17 Centre National De La Recherche Scientifique (C.N.R.S.) A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
WO2002042842A2 (en) 2000-11-22 2002-05-30 Allergan, Inc. A high-throughput screen for identifying channel blockers that selectively distinguish transient from persistent sodium channels
US6479458B1 (en) 2001-11-08 2002-11-12 Allergan, Inc. Targeting the reverse mode of the Na+/Ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
US7361478B2 (en) 2001-11-20 2008-04-22 Allergan, Inc. High-throughput screen for identifying selective persistent sodium channels channel blockers
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
EP1924326B1 (en) 2005-08-25 2016-10-12 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
EP2243476A1 (en) * 2009-04-17 2010-10-27 Centre National de la Recherche Scientifique Compounds for the treatment of mitochondrial diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US5236940A (en) * 1988-12-15 1993-08-17 Rhone-Poulenc Sante Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation
EP0374041B1 (fr) * 1988-12-15 1992-06-17 Rhone-Poulenc Sante Médicaments à base de dérivés de la benzothiazolamine-2, dérivés et leur préparation
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
ATE191342T1 (de) 2000-04-15
ES2145902T3 (es) 2000-07-16
PT738147E (pt) 2000-08-31
WO1995019170A1 (fr) 1995-07-20
IL112288A (en) 1999-04-11
EP0738147B1 (fr) 2000-04-05
JPH09507498A (ja) 1997-07-29
US5686475A (en) 1997-11-11
AU1458495A (en) 1995-08-01
EP0738147A1 (fr) 1996-10-23
FR2714828A1 (fr) 1995-07-13
JP3585045B2 (ja) 2004-11-04
ZA95150B (en) 1995-09-07
DE69516110D1 (de) 2000-05-11
IL112288A0 (en) 1995-03-30
FR2714828B1 (fr) 1996-02-02
GR3033005T3 (en) 2000-07-31
DE69516110T2 (de) 2000-09-28

Similar Documents

Publication Publication Date Title
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
DE701443T1 (de) Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DK0527835T3 (da) Doseringsform til afgivelse af et anti-Parkinsonmiddel
DK0738147T3 (da) Anvendelse af riluzol ved behandling af mitochondriesygdomme
DE69515038T2 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
SE8703066L (sv) Antiseptisk komposition innehallande etylalkohol och monolaurin
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DK0796103T3 (da) Anvendelse af røgelse til behandling af Alzheimer-sygdommen
BR9708388A (pt) Solução aquosa de hemoglobina polimerizada piridoxilada e processo de sua preparação.
NO963186L (no) Neurobeskyttende kromanforbindelser
GB9421472D0 (en) Novel methods
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
KR920009403A (ko) 수면장해 치료용 이미다조벤조디아제핀
RU94020964A (ru) Электростатический пластырь "элпласт"
RU2000108989A (ru) Способ профилактики и лечения респираторных болезней телят